Sign in to view content

Brolucizumab for the Treatment of Visual Impairment Due to Diabetic Macular Edema: 52-Week Results From the KESTREL and KITE Studies

David M. Brown, MD

Video
Published 2021

Related

Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022
Treatment Switch From Aflibercept to Ranibizumab Pre-filled Syringe in Canadian nAMD and DME Patients in a Real-World Setting: The PRECISE Study
Ananda Kalevar, MD, FRCS(C), DABO
On Demand Cases, Courses, and Papers
2020
Outcomes of DRCR Network Treatment Regimen Starting with Observation for Eyes With Center-involved Diabetic Macular Edema and Good Visual Acuity
Omar S. Punjabi, MD
Updates from the Field
2019

Category: Diabetic Retinopathy

See more